Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic LeukemiaShannon L. Maude, Stephan A. Grupp, Theodore W. Laetsch et al.|New England Journal of Medicine|2018Cited by 5.7k
Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA TrialTheodore W. Laetsch, Stephan A. Grupp, Shannon L. Maude et al.|Journal of Clinical Oncology|2022Cited by 369
Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic LeukemiaStephan A. Grupp, Hidefumi Hiramatsu, Shannon L. Maude et al.|Blood|2018Cited by 94
Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trialTheodore W. Laetsch, Andrew C. Harris, Gary Douglas Myers et al.|The Lancet Oncology|2019Cited by 90
Analysis of a Global Registration Trial of the Efficacy and Safety of CTL019 in Pediatric and Young Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)Stephan A. Grupp, Michael A. Pulsipher, Theodore W. Laetsch et al.|Blood|2016Cited by 83